Compare Neurocrine Biosciences Inc (NBIX) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.7 (market cap $15.77B), while Abrdn Physical Platinum Shares ETF trades at $16.66. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | PPLT | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $185.50 | $25.23 |
52-Week Low | $123.10 | $12.38 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
PPLT, the Aberdeen Physical Platinum Shares ETF, trades at $16.46, down 0.24% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights platinum's underperformance relative to gold and silver, suggesting potential catch-up trade opportunities. The ETF tracks physical platinum prices, offering exposure to industrial and precious metal demand without direct company financials.
Outlook hinges on platinum's price recovery amid industrial demand and precious metal trends. Risks include commodity volatility and macroeconomic shifts. Analyst sentiment is cautiously optimistic for a rally, but investors face metal-specific supply-demand uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
